Plain-English translation of NCT05609994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether combining a new drug called vorasidenib with a personalized vaccine can help treat low-grade brain tumors that have come back after initial treatment. The vaccine is custom-made based on your tumor's specific characteristics, and the medication works by blocking a protein that helps these tumors grow. Researchers want to see if using both together is safe and more effective than either treatment alone.
Low-grade brain tumors often come back even after initial surgery or other treatments, and patients need better options. This trial exists to see whether training your immune system (through the vaccine) combined with stopping tumor growth (through the medication) could help prevent tumors from returning or slow their growth.
You likely qualify if…
You likely don't qualify if…
You would receive a tetanus booster shot first, then take the medication vorasidenib by mouth once daily for 28-day cycles. Starting in the third cycle, you would also receive the personalized vaccine as injections under the skin in your groin area on a set schedule. Over about 14 cycles (roughly 14 months), you would receive up to 12 vaccine doses alongside the daily medication. You would need regular blood tests and imaging scans to monitor how the treatment is working and watch for side effects.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States